Arsenal Bio
Main focus: Next-generation autologous T cell therapies
Company stage: Commercial
Diseases (gene editing): Cancer
Genome editing tool: CRISPR
Funding stage: Private
Location: South San Francisco, CA, USA
Website: https://www.arsenalbio.com/
Gene editing partnerships: Bristol Myers Squibb
Arsenal Bio develops multiple proprietary technology platforms, CellFoundry™, PrimeR™ and CARchitecture™ which together with the CRISPR technology form the foundation for its next-generation therapies. While the company has yet to disclose its lead programmes, it has announced a collaboration with Bristol Myers Squibb (BMS) where the two companies will discover and develop T cell therapies for the treatment of solid tumours.